SCHEDULE 13D/A: Fortress Biotech Amends Mustang Bio Stake, Retains Voting Majority Through Preferred Stock

Fortress Biotech, Inc. has filed an Amendment No. 5 to its Schedule 13D, updating its beneficial ownership in Mustang Bio, Inc. to 7.9% and reaffirming its control through Class A preferred stock.

Summary

• Fortress Biotech, Inc. (Reporting Person) filed an Amendment No. 5 to its Schedule 13D regarding its stake in Mustang Bio, Inc. (Issuer).
• The Reporting Person beneficially owns 199,191 shares of Mustang Bio's common stock, representing 7.9% of the outstanding shares.
• This ownership includes 250,000 shares of Class A preferred stock, which are convertible into 333 shares of common stock.
• The Class A preferred stock grants Fortress Biotech a voting majority in Mustang Bio at all times.
• Fortress Biotech also holds 1,333 shares of common stock underlying Warrants, exercisable until July 15, 2035, at an exercise price of $110.25 per share.
• The filing was triggered by the issuance of 67,806 shares of Mustang Bio common stock to Fortress Biotech as "Offering Equity Grants" under a Founders Agreement.
• Under the Founders Agreement, Fortress Biotech receives an equity fee equal to 2.5% of the gross amount of any Mustang Bio equity or debt financing.

Sentiment

Score: 6

Explanation: The filing is largely neutral as it's a routine update to a beneficial ownership statement. The continued control by Fortress Biotech through preferred stock and ongoing equity grants from Mustang Bio's financings indicate a stable, long-term strategic relationship, which can be viewed positively for stability but negatively for common shareholder influence.

Positives

• Fortress Biotech maintains a significant strategic stake and voting control in Mustang Bio, indicating continued commitment.
• The Founders Agreement provides Fortress Biotech with ongoing equity grants based on Mustang Bio's financing activities, aligning interests.

Negatives

• The Class A preferred stock structure grants Fortress Biotech a perpetual voting majority, potentially limiting the influence of common shareholders.
• The Warrants held by Fortress Biotech's executives have a high exercise price ($110.25), which may be significantly out of the money depending on current share price, potentially indicating a long-term view or a historical valuation.

Risks

• Concentrated Voting Control: Fortress Biotech's Class A preferred stock ensures it "will at all times constitute a voting majority," which could limit the ability of other shareholders to influence corporate governance or strategic decisions.
• Dilution from PIK Dividends: The Class A preferred stock receives pro rata PIK Dividends in common stock equal to 2.5% of Mustang Bio's fully-diluted outstanding capitalization annually, which could lead to ongoing dilution for common shareholders.
• Potential for Conflicts of Interest: The Founders Agreement and Warrants involve related parties (Fortress Biotech and its executives) and could present potential conflicts of interest, although not explicitly stated as a risk in the document.

Future Outlook

The document indicates an ongoing financial relationship between Fortress Biotech and Mustang Bio through the Founders Agreement, where Fortress Biotech will continue to receive equity grants based on future equity or debt financings by Mustang Bio. The Class A preferred stock structure ensures Fortress Biotech maintains a voting majority in Mustang Bio indefinitely, suggesting a long-term strategic alignment and control.

Industry Context

This filing highlights a common strategic relationship in the biotechnology sector where a larger, established biotech firm (Fortress Biotech) maintains a significant, controlling stake in a smaller, developing entity (Mustang Bio), often providing funding and strategic oversight. This structure allows the parent company to leverage the smaller entity's R&D while maintaining governance control, a model frequently seen in venture-backed or spin-off biotech companies.

Comparison to Industry Standards

• The arrangement where a parent company retains a voting majority through a special class of preferred stock, as seen with Fortress Biotech's Class A preferred stock in Mustang Bio, is a common mechanism for maintaining control in spin-offs or strategic investments within the biotech and pharmaceutical industries. For instance, similar structures can be observed in companies like Roivant Sciences, which often creates and funds 'Vants' (subsidiary companies) where it retains significant control and economic interest.
• The 2.5% equity fee on financings, while specific, is a form of 'carry' or 'management fee' that aligns with venture capital or incubator models, though typically these are tied to fund performance rather than gross financing amounts.
• The high exercise price of the warrants ($110.25) suggests they were issued at a much higher historical valuation or are intended as long-term incentives tied to significant future growth, which is not uncommon for long-term incentive plans in high-growth sectors like biotech, though specific comparable companies or projects are not detailed in the filing.

Corporate Governance

Legal Proceedings

• The Reporting Person (Fortress Biotech, Inc.) has not been convicted in any criminal proceeding (excluding traffic violations or similar misdemeanors) during the last five years.
• The Reporting Person has not been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction resulting in it being subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws during the last five years.

Related Party Transactions

• Fortress Biotech, Inc. is party to a Second Amended and Restated Founders Agreement with Mustang Bio, Inc., under which Mustang Bio pays Fortress Biotech an equity fee (Offering Equity Grant) equal to 2.5% of the gross amount of any Issuer equity or debt financing.
• Fortress Biotech, Inc. issued Common Stock Warrants to Lindsay A. Rosenwald, M.D. (Fortress Biotech's Chairman, President and CEO) and Michael S. Weiss (Fortress Biotech's Executive Vice Chairman, Strategic Development), which are exercisable for 1,333 shares of Mustang Bio common stock. Mr. Weiss also serves as Executive Chairman of Mustang Bio's Board, and Dr. Rosenwald is a board member.

Stakeholder Impact

• Shareholders (Common Stock): The perpetual voting majority held by Fortress Biotech through its Class A preferred stock significantly limits the influence and voting power of common shareholders. Ongoing PIK Dividends and Offering Equity Grants paid in common stock could lead to dilution.
• Management/Board: The presence of Fortress Biotech executives (Dr. Rosenwald and Mr. Weiss) on Mustang Bio's board ensures alignment with Fortress Biotech's strategic interests, potentially influencing Mustang Bio's operational and financial decisions.
• Creditors/Investors (Debt/Equity): The Founders Agreement ensures Fortress Biotech receives a percentage of future financings, which could impact the net proceeds available to Mustang Bio from such raises, but also indicates a stable, controlling investor relationship.

Next Steps

• Fortress Biotech will continue to receive PIK Dividends in common stock from Mustang Bio on each January 1st until the Class A preferred stock is converted or redeemed.
• Fortress Biotech will continue to receive Offering Equity Grants equal to 2.5% of any future equity or debt financings undertaken by Mustang Bio.

Key Dates

Keywords

Fortress Biotech, Mustang Bio, Schedule 13D, Beneficial Ownership, Class A Preferred Stock, Voting Control, Equity Grants, Founders Agreement, Warrants, SEC Filing, Biotechnology, Pharmaceutical